Navigation Links
Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
Date:2/23/2011

n in New York in May 2010. The 10-week, randomized, double-blind study compared the effect of CLD and HCTZ, both in combination with azilsartan medoxomil, on systolic and diastolic blood pressure (SBP, DBP) by clinic blood pressure measurement and by ambulatory blood pressure monitoring (ABPM) in 609 patients with hypertension.

About HypertensionHypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated at levels of 140 mm Hg or greater systolic or 90 mm Hg or greater diastolic. Hypertension impacts approximately 75 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation’s health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About Fixed-Dose Combination of Azilsartan Medoxomil Plus ChlorthalidoneDeveloped by Takeda, azilsartan medoxomil plus chlorthalidone is an investigational fixed-dose combination for the treatment of hypertension, or high blood pressure. The fixed-dose combination of azilsartan medoxomil plus chlorthalidone contains two medications, azilsartan medoxomil, an angiotensin II receptor blocker, and chlorthalidone, a long-acting thiazide-like diuretic used in the treatment of hypertension. The most commonly reported adverse drug reactions occurring in at least two percent of azilsartan medoxomil plus CLD-treated patients at the recommended doses and greater than azilsartan medoxomil or chlorthalidone monotherapies were increased blood creatinine (11%), diz
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
3. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
4. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Takeda Responds to FDA Advisory Committee Recommendation
7. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
8. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
9. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 An experimental drug ... as a viable first treatment for anemia of inflammation, according ... the treatment published online today in Blood ... (ASH).    Anemia is a condition that ... do not function properly. When an individual has anemia, the ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com ... report is available in its catalogue: ... Application and Approval of Imported Medical ... (2014 Edition) ... Now, Chinese regulations on medical devices ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10
... Reinforces Anti-Inflammatory Properties of Red Hot ,Super,Fruit, ... study shows tart cherries,one of today,s hottest "Super ... of type 2 diabetes and cardiovascular disease,in animals. ... researchers,today at the Experimental Biology annual meeting. As ...
... 2008 Data from five studies sponsored,by Ortho ... National Kidney,Foundation (NKF) 2008 Spring Clinical Meetings from ... PROCRIT(R) (Epoetin alfa)., The data include studies ... (EPO) and darbepoetin alfa (DARB), evaluate medical costs,related ...
Cached Medicine Technology:Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease 2Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6
(Date:8/28/2014)... (PRWEB) August 28, 2014 Edvance360 ... the top ten tools for online teaching, as well ... for Best Course or Learning Management System, announced that ... Academy, Typewell, Dialysis Treatment Center of America, Metis Leadership ... and HMG Plus, to the user community. , ...
(Date:8/28/2014)... 2014 Every year, cataracts affect over 22 ... the leading cause of blindness in the world. Characterized by ... the iris, cataracts are estimated to affect an additional 30 ... aging population. Cataracts are just one of the many conditions ... Tracy of Carlsbad Eye Care screens patients for a number ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Labor Day ... the beach and those last glorious glimpses of summer. ... patients are planning on spending their long weekend recovering ... Sadati, a board certified facial plastic and reconstructive surgeon ... patients have taken advantage of their holiday weekends to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Atlantic Information ... of the latest addition to its Management Insight Series, ... a Major Patient Privacy/Security Risk . The new report ... manage the risks associated with portable electronic devices, and ... federal requirements. , With expert advice on how to ...
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Cataract Awareness Month an Opportunity to Focus on Vision Care and Ocular Health 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4Health News:New Report Offers Best Practices for Avoiding the Patient Privacy/Security Risks Posed by Mobile Devices 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4
... July 7 HealthSouth,Corporation (NYSE: HLS ) ... to acquire a 30-bed inpatient rehabilitation unit at ... is currently owned by Columbia,Medical Center of Arlington ... operations will relocate to HealthSouth Rehabilitation,Hospital of Arlington., ...
... recycling benefits our planet; and now new research suggests ... cancer. Scientists at Stanford University have identified a molecule ... cells. The research, published by Cell Press in the ... , may drive treatment strategies for cancer in an ...
... and geographic boundaries are some of the challenges that ... for a possible influenza pandemic, according to a new ... who are leading planning efforts for an influenza outbreak ... defined by political lines," said George Avery, an assistant ...
... Pa., July 7 Digestive Care, Inc. (DCI),announced today ... New Drug,Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the ... and Drug,Administration ("FDA"). The FDA has granted the product ... used to treat EPI for over,a decade and we ...
... Satisfaction Rate 94% - 100%, ARLINGTON HEIGHTS, ... after an elective mastectomy are satisfied with,their decision, ... do it,again, reports a study in July,s Plastic ... American Society of Plastic Surgeons,(ASPS). In addition, breast ...
... Ill. Women who have breast reconstruction after an ... complication rates and 98 percent would do it again, ... Surgery , the official medical journal of the American ... reconstruction after preventive mastectomy was as safe as or ...
Cached Medicine News:Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 2Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 3Health News:Can recycling be used to treat cancer? 2Health News:Political borders, health-care issues complicate pandemic planning 2Health News:Political borders, health-care issues complicate pandemic planning 3Health News:Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase) 2Health News:98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study 2Health News:98 percent of elective mastectomy patients would have reconstruction again, says ASPS study 2
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... the ease and comfort you've come to expect ... in clinical trials agreed that the BD Lancet ... settings allow you to choose the best lancet ... lancets, the device also helps eliminate the "vibrations" ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
Medicine Products: